14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
PACS vs SGRY: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, PACS Group, Inc. (PACS) is the stronger overall head-to-head candidate over Surgery Partners, Inc. (SGRY) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). PACS carries a Unified Composite Score of 46.8/100 (HOLD) at $43.67 (15.3x Forward P/E, 7.4% operating margin), whereas SGRY carries 29.6/100 (SELL) at $26.78 (N/M Forward P/E, 13.2% operating margin).
Competes within the Medical Care Facilities value chain with $3.5B market capitalization and 13.2% operating margin.
OpEx & R&D Reinvestment9.0% of Rev ($302M)
90D Engineering Disclosures0 Published
Investor FAQ PACS vs SGRY Key Questions & Quantitative Answers
As of Nov 20, 2026, PACS Group, Inc. (PACS) is the stronger overall head-to-head candidate over Surgery Partners, Inc. (SGRY) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). PACS carries a Unified Composite Score of 46.8/100 (HOLD) at $43.67 (15.3x Forward P/E, 7.4% operating margin), whereas SGRY carries 29.6/100 (SELL) at $26.78 (N/M Forward P/E, 13.2% operating margin). Technically, PACS sits in a Neutral phase (RSI 39.2, CONSOLIDATION options structure) and SGRY sits in a Markup phase (RSI 84.4, SURGE options structure).
PACS leads the Growth & Scale pillar: PACS posts +11.5% YoY revenue growth and +15.6% YoY earnings growth on $5.71B TTM revenue (17.8% gross margin, 7.4% operating margin), compared with SGRY at -0.8% YoY revenue growth and +0.0% YoY earnings growth on $3.36B TTM revenue (22.2% gross margin, 13.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), PACS cumulative revenue shifted +120.4% while SGRY shifted +87.0%. In operating R&D and SG&A reinvestment, PACS deploys 10.4% of Rev ($593M) (0 90-day corporate R&D disclosures) versus 9.0% of Rev ($302M) (0 disclosures) for SGRY.
PACS screens cheaper on headline valuation multiples. PACS trades at 15.3x Forward P/E, 26.2x Trailing P/E, 1.22x PEG, and 1.8x EV/Revenue (0.1% FCF margin), whereas SGRY trades at N/M Forward P/E, N/M Trailing P/E, 1.66x PEG, and 1.9x EV/Revenue (6.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PACS (26.5% ROE) versus SGRY (2.1% ROE) capital efficiency.
In options market volatility and institutional positioning, PACS carries 46.1% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.52x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.78β · 51% Vol realized risk). By comparison, SGRY carries 62.1% implied volatility (34th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.87β · 166% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.